Japan`s Drug Committee Approves Bristol-Myers Squibb SGLT-2 Inhibitor
This article was originally published in PharmAsia News
Japan Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) First Committee on Drugs gave the green light for Bristol-Myers Squib SGLT-2 inhibitor Fosyga (dapagliflozin), also known as Farxiga in the United States.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.